Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 10/17/2025 | CALL | $25.00 | 864 | +377 | +77.41% |
| 05/15/2026 | CALL | $30.00 | 55 | +44 | +400.00% |
| 10/17/2025 | CALL | $27.00 | 156 | +40 | +34.48% |
| 01/15/2027 | CALL | $37.00 | 84 | +32 | +61.54% |
| 01/15/2027 | CALL | $20.00 | 99 | +30 | +43.48% |
| 11/21/2025 | CALL | $30.00 | 109 | +21 | +23.86% |
| 01/15/2027 | PUT | $15.00 | 21 | -10 | -32.26% |
| 11/21/2025 | CALL | $24.00 | 162 | -12 | -6.90% |
| 12/19/2025 | CALL | $29.00 | 91 | -14 | -13.33% |
| 12/19/2025 | CALL | $28.00 | 60 | -19 | -24.05% |
| 02/20/2026 | CALL | $15.00 | 145 | -23 | -13.69% |
| 12/19/2025 | CALL | $30.00 | 772 | -55 | -6.65% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| ARK ETF Tr-ARK Innovation ETF | 8.35% | 6.24M | 200.4M |
| ARK ETF Tr-ARK Genomic Revolution ETF | 2.80% | 2.09M | 67.32M |
| Vanguard Total Stock Market Index Fund | 2.71% | 2.03M | 65.1M |
| Vanguard Small-Cap Index Fund | 2.31% | 1.72M | 55.43M |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.18% | 1.63M | 52.24M |
| iShares Russell 2000 ETF | 1.87% | 1.4M | 44.9M |
| Vanguard Small-Cap Growth Index Fund | 1.33% | 996.91k | 32.04M |
| Vanguard Extended Market Index Fund | 1.09% | 811.48k | 26.08M |
| Fidelity Select Portfolios - Biotechnology | 0.90% | 669.38k | 21.51M |
| Fidelity Small Cap Index Fund | 0.70% | 525.26k | 16.88M |
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
06/28 09:10 am
The Motley Fool
Read moreEditas Medicine Is Great. Here's Why You Shouldn't Buy It.
06/17 10:07 am
The Motley Fool
Read moreBeam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
05/29 04:01 pm
GlobeNewswire Inc.
Read moreWhy Beam Therapeutics Stock Tanked on Tuesday
05/06 05:05 pm
The Motley Fool
Read moreBeam Therapeutics Announces Pricing of Underwritten Offering
03/10 06:01 am
GlobeNewswire Inc.
Read moreBeam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
02/24 08:00 am
GlobeNewswire Inc.
Read moreBeam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
01/30 08:00 am
GlobeNewswire Inc.
Read moreComprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight
12/19 02:00 pm
GlobeNewswire Inc.
Read moreBeam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
12/08 02:45 pm
GlobeNewswire Inc.
Read moreBeam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
12/07 12:30 pm
GlobeNewswire Inc.
Read moreBeam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
12/06 08:00 am
GlobeNewswire Inc.
Read moreDown 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
11/24 06:47 am
The Motley Fool
Read moreGene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%
09/10 04:51 am
GlobeNewswire Inc.
Read moreBeam Therapeutics Announces Transition of Chief Financial Officer - GlobeNewswire
07/15 06:32 am
GlobeNewswire Inc.
Read moreHere's Why You Should Invest in Beam Therapeutics (BEAM) Now - Zacks Investment Research
07/11 12:01 pm
Zacks Investment Research
Read moreBeam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
06/27 10:26 am
Zacks Investment Research
Read moreBeam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
06/26 06:30 am
GlobeNewswire Inc.
Read moreBeam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
06/14 03:00 am
GlobeNewswire Inc.
Read moreWhy Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
06/06 11:31 am
Zacks Investment Research
Read moreBeam Therapeutics to Participate in Jefferies Global Healthcare Conference
05/30 06:30 am
GlobeNewswire Inc.
Read moreBeam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
05/08 10:52 am
Zacks Investment Research
Read moreBeam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
05/08 06:30 am
GlobeNewswire Inc.
Read moreBeam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
05/07 06:30 am
GlobeNewswire Inc.
Read moreUltragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
05/02 05:10 pm
Zacks Investment Research
Read moreBeam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
05/01 10:01 am
Zacks Investment Research
Read moreExpert Ratings For Beam Therapeutics
04/23 02:00 pm
Benzinga
Read moreTracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
04/19 03:54 am
Seeking Alpha
Read moreWhy Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
03/28 11:30 am
Zacks Investment Research
Read moreExpert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
03/27 11:01 am
Benzinga
Read moreBeam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
02/28 07:30 am
GlobeNewswire Inc.
Read moreBrian's Big Idea on Healthcare
02/27 04:39 pm
Zacks Investment Research
Read moreNorwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
02/27 11:27 am
Benzinga
Read moreBeam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
02/27 07:30 am
GlobeNewswire Inc.
Read moreHarmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
02/22 09:45 am
Zacks Investment Research
Read moreEarnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline
02/20 11:00 am
Zacks Investment Research
Read more5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
02/15 06:45 am
Zacks Investment Research
Read moreCathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss
02/09 12:49 am
Benzinga
Read moreBeam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
02/05 07:30 am
GlobeNewswire Inc.
Read moreWhy Beam Therapeutics Stock Zoomed 17% Higher Today
01/29 07:21 pm
The Motley Fool
Read more3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
01/16 10:00 am
The Motley Fool
Read moreBeam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
01/08 07:30 am
GlobeNewswire Inc.
Read more4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
01/08 06:52 am
The Motley Fool
Read moreBEAM Stock Rallies More Than 25% in 3 Months: What Next?
01/03 11:52 am
Zacks Investment Research
Read moreBeam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
01/02 07:30 am
GlobeNewswire Inc.
Read more2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street
12/27 11:30 am
The Motley Fool
Read moreThe Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics
12/14 11:36 am
Zacks Investment Research
Read more